Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

VOZMOZhNOSTI PRIMENENIYa STATINOV DLYa PROFILAKTIKI OSTEOPOROZAObzor literatury

Abstract



N S Kryzhova

L Ya Rozhinskaya

  1. Насонов Е.Л. Перспективы применения статинов в ревматологии // РМЖ. 2003. No 23 (195). Т. 11. С. 1273-1276.
  2. Скрипникова И.А. Взаимосвязь генерализованного остеопороза и сердечно-сосудистых заболеваний, обусловленных атеросклерозом у женщин постменопаузального периода // Остеопороз и остеопатии. 2001. No 3, С. 27-33.
  3. Шварц Г.Я. Современное состояние лекарственной терапии атеросклероза // Хим. фарм. журн. 1990. No 8. С. 13-22.
  4. Шварц Г.Я. Фармакотерапия остеопороза. М.: Медицинское информационное агентство, 2002. 368 с.
  5. Шварц Г.Я. Статины и формирование кости // Остеопороз и остеопатии. 2003. No 3. С. 17-20.
  6. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling // Osteoporos Int. 2001. V. 12(5). P. 380-384.
  7. Chan K.A., Andrade S.E., Boles M. et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women // Lancet. 2000. V. 355. P. 2185-2188.
  8. Chan M.H., Mak T.W., Chiu R.W. et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. // J. Clin Endocrinol Metab. 2001. Sep. V. 86(9). P. 4556-9.
  9. Garrett I.R., Gutierrez C., Mundy G.R. Statins and bone formation // Curr.Pharm. Design. 2001. V. 7. P. 715-736.
  10. LaCroix A.Z., Cauley J.A., Pettinger M. et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study // Ann Intern Med. 2003. Jul 15. V. 139(2). P. 97-104.
  11. Luckman S.P., Hughes D.E., Coxon F.P. et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GNP-binding proteins, including Ras // J. Bone Miner. Res. 1998. V. 13. P. 581-589.
  12. McClung M., Kiel D., Lindsay R. et al. A 12-Month, dose-response study of atorvastatin effects on bone in postmenopausal women // JBMR - January, 2004. V. 19. Num. 1. P. 11-17.
  13. Meier C.R., Schlienger R.G., Kraenzlin M.E. et al. HMG-CoA reductase inhibitors and the risk of fractures // JAMA. 2000. V. 283. P. 3205-3210.
  14. Mostaza J.M., De la Piedra C., Curiel M.D. et al. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women // Clin Chim Acta. 2001. Jun. V. 308(1-2). P. 133-137.
  15. Mundy G., Garrett R., Harris S. et al. Stimulation of bone formation in vitro and in rodents by statins // Science. 1999. Vol. 286. P. 1946-1949.
  16. Pasco J.A., Kotowicz M.A., Henry M.J. et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study // Arch Intern Med. 2002. Mar. 11. V. 162(5). P. 537-540.
  17. Poli A., Bruschi F., Cesana B. et al. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women // Obstet Gynecol. 2003. Nov. V. 102(5 Pt 1). P. 922-926.
  18. Rejnmark L., Buus N.H., Vestergaard P. et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women // JBMR. May 2004. V. 19, Num. 5. P. 737-744.
  19. Rejnmark L., Buus N.H., Vestergaard P. et al. Statins decrease bone turnover in postmenopausal women: a cross-sectional study // Eur J Clin Invest. 2002. Aug. V. 32(8). P. 581-9.
  20. Reid I.R., Hague W., Emberson J. et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease // Lancet. 2001. Feb. 17. V. 357(9255). P. 509-512.
  21. Stein E.A., Farnier M., Waldstreicher J. et al. Simvastatin Effects of statins on biomarkers of bone metabolism: a randomised trial // Nutr Metab Cardiovasc Dis. 2001. Apr. V. 11(2). P. 84-87.
  22. Van Beek E., Lowik C., Van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates // J. Bone Miner.Res. 1999. Vol. 14. P. 722-729.
  23. Van Beek E., Pieterman E., Cohen L. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates // Biochem. Biophys. Res. Commun. 1999. V. 264. P. 108-111.
  24. Van Staa T.P., Wegman S., de Vries et al. Use of statins and risk of fractures // JAMA. 2001. V. 285. P. 1850-1855.
  25. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients // JAMA. 2000. V. 283. P. 3211-3216.
  26. Whitfield J.F. Statins: new drugs for treating osteoporosis? // Expert Opin Investig Drugs. 2001. Mar. V. 10(3). P. 409-15. Review.

Views

Abstract - 397

PDF (Russian) - 290

PlumX


Copyright (c) 2005 Kryzhova N.S., Rozhinskaya L.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.